A newly published observational study raises a provocative question: could medications originally designed to treat diabetes and obesity also help lower the risk of developing breast cancer? The answer is not yet known—but the early signals are attracting attention across oncology, obesity medicine, and prevention science.
Researchers analyzed electronic health record data from 111,646 women aged 45–80 years with overweight or obesity (BMI ≥25) who underwent breast imaging between 2022 and 2025. Among them, approximately 15,000 women had been exposed to GLP-1 receptor agonists before breast imaging.
The findings were striking.
Women who had received GLP-1 therapy experienced a significantly lower incidence of breast cancer compared with women who had not. After adjusting for important factors—including age, race, ethnicity, BMI, breast density, and diabetes status—GLP-1 exposure remained associated with approximately a 30% lower likelihood of breast cancer detection.
Importantly, the researchers reported:
- Breast cancer incidence of 1.62% among women exposed to GLP-1 therapy
- Breast cancer incidence of 2.31% among matched women without GLP-1 exposure
- An absolute risk reduction of 0.69% across the study period
Why This Matters for CancerFitness.org
For years, Exercise Oncology has emphasized a central concept:
Body composition, metabolic health, inflammation, and physical activity all influence cancer outcomes.
This study adds another layer to that conversation.
GLP-1 medications may not simply reduce body weight—they may also influence:
- Metabolic signaling
- Insulin pathways
- Chronic inflammation
- Cellular energy metabolism
- Potentially the tumor microenvironment itself
Yet for cancer survivors and individuals seeking prevention, there is an essential message:
Medication should not replace movement.
Exercise remains one of the most evidence-supported interventions for:
- Reducing excess adiposity
- Improving insulin sensitivity
- Preserving lean muscle mass
- Lowering inflammation
- Improving quality of life and survivorship outcomes
For patients taking GLP-1 therapies, structured Exercise Oncology programs may become increasingly important to preserve strength and function while maximizing metabolic health.
A Word of Caution
This was not a randomized clinical trial and does not prove that GLP-1 drugs prevent breast cancer. The authors emphasize that the findings are hypothesis-generating, and prospective trials are still needed before changing clinical practice.
Still, the implications are exciting: prevention strategies in the future may combine exercise, nutrition, weight optimization, and precision metabolic therapies rather than relying on any single intervention.
Call to Action
At CancerFitness.org, we believe the future of cancer prevention and survivorship lies in integrated Exercise Oncology programs—where movement, metabolic health, nutrition, and evidence-based medical therapies work together.
If you are living with overweight, obesity, active breast cancer, or long-term survivorship:
Talk with your healthcare team about your personal prevention and survivorship plan—and make exercise a core component of that strategy.
Reference: GLP-1 agonists are associated with a significant reduction in breast cancer incidence in women. Elizabeth S. McDonald, MD, PhD, Laura B. Gillis, PhD, Peter Gabriel, MD, Kham Xapakdy, MS, et al. Accepted Unedited Manuscript, JCO Oncol Pract 10.1200/ OP-26-00485R1. Epub 2026 June 02.
